Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Doxofylline→

Doxofylline Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
69975-86-6
Molecular formula
C11H14N4O4
Molecular weight
266.25 g/mol
Drug class
Methylxanthine bronchodilatorxanthine derivative
Mechanism of action
The exact molecular mechanism is not fully resolved. Doxofylline produces bronchodilation and has been described as modulating phosphodiesterase/cyclic-AMP signalling; unlike theophylline, it has markedly reduced affinity for adenosine receptors and does not show the same adenosine-antagonist profile.
Indications / reported uses
  • Bronchial asthma
  • Chronic obstructive pulmonary disease (COPD) and other obstructive airway conditions where doxofylline is authorised; indication and formulation differ by jurisdiction

Sources: MIMS India — Doxofylline information · PubChem — Doxofylline and ChEBI summary · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Methylxanthine bronchodilator; xanthine derivative

Mechanism of action

The exact molecular mechanism is not fully resolved. Doxofylline produces bronchodilation and has been described as modulating phosphodiesterase/cyclic-AMP signalling; unlike theophylline, it has markedly reduced affinity for adenosine receptors and does not show the same adenosine-antagonist profile.

General use cases

  • Bronchial asthma
  • Chronic obstructive pulmonary disease (COPD) and other obstructive airway conditions where doxofylline is authorised; indication and formulation differ by jurisdiction

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Doxofylline Environmental Risk Assessment (ERA) (the Doxofylline ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.